Zasocitinib, Plaque Psoriasis, TYK2 Inhibitors, TAK-279, Dermatology

Zasocitinib, Plaque Psoriasis, TYK2 Inhibitors, TAK-279, Dermatology

Zasocitinib: JH2 Selectivity, Phase 3 Efficacy, and the Road to Best-in-Class TYK2 Status in Plaque Psoriasis

Phase 3 LATITUDE data positions zasocitinib well above apremilast, while the pending NCT06973291 head-to-head trial against deucravacitinib will ultimately determine best-in-class standing among TYK2 inhibitors. See Disclaimer below * Plaque psoriasis affects approximately 7 million patients in the US, roughly 2.0 to 2.4 million of whom carry moderate-to-severe disease.